CD8A and neoplasm: The most relevant predictive biomarkers for cSCC, particularly in cases with PNI, include tumor programmed death-ligand 1 (PD-L1) expression, the presence and phenotype of tumor-infiltrating lymphocytes (especially CD8+ T cells expressing immune checkpoints), and gene expression signatures associated with immune activation [26,27,28].